A Randomised, Double-blind, Placebo-controlled, Crossover Study to Evaluate Efficacy and Safety of the CRF1 Receptor Antagonist GW876008 in Patients With Irritable Bowel Syndrome

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Crossover Study to Evaluate Efficacy and Safety of the CRF1 Receptor Antagonist GW876008 in Patients With Irritable Bowel Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Emicerfont (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2008 Results are expected in the second half of 2008 according to Neurocrine media release.
    • 05 Feb 2008 Status changed from recruiting to in progress according to Neurocrine media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top